ArgGlyAsp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts☆
References (47)
Cell
(1987)Immunol. Today
(1988)- et al.
Cell
(1986) - et al.
J. Biol. Chem
(1987) - et al.
J. Biol. Chem
(1987) - et al.
Exp. Cell Res
(1989) - et al.
J. Biol. Chem
(1988) - et al.
Dev. Biol
(1989) J. Oral Pathol
(1983)J. Clin. Pathol
(1985)
Physiol. Rev
(1986)
Clin. Orthop
(1988)
Clin. Orthop
(1977)
Science
(1987)
J. Bone Min. Res
(1989)
J. Cell Biol
(1989)
Int. J. Exp. Pathol
(1990)
Calcif. Tissue Int
(1990)
J. Bone Min. Res
(1990)
Cancer Res
(1985)
Endocrinology
(1986)
Cited by (223)
Osteoclast biology
2020, Marcus and Feldman’s OsteoporosisMolecular signaling in bone cells: Regulation of cell differentiation and survival
2019, Advances in Protein Chemistry and Structural BiologyInhibition of osteoporosis by the αvβ3 integrin antagonist of rhodostomin variants
2017, European Journal of PharmacologyA novel small-molecule PPI inhibitor targeting integrin α<inf>v</inf>β<inf>3</inf>-osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice
2016, BiomaterialsCitation Excerpt :No FDA-approved integrin αvβ3 antagonists are on the market, but several compounds have shown efficacy in preclinical evaluations and are currently in clinical trials for treatment of osteoporosis. Specifically, anti-αvβ3 antibodies [58], as well as peptides and proteins containing the RGD motif recognized by integrin [58,59], inhibit bone degradation in vitro. Orally active, nonpeptide RGD mimetic αvβ3 antagonists have been generated [60–62], some of which increase BMD in women with postmenopausal osteoporosis [17].
Osteoclast Biology
2013, Osteoporosis: Fourth Edition
- ☆
Part of these data were presented in preliminary form at the 12th Annual Meeting of the American Society for Bone and Mineral Research, August 28–31 1990, Atlanta, Georgia.
Copyright © 1991 Published by Elsevier Inc.